Co-Exclusive License Agreement Sample Contracts

Text Marked by [* * *] Has Been Omitted Pursuant to a Request for Confidential Treatment and Was Filed Separately With the Securities and Exchange Commission. EXCLUSIVE AND CO-EXCLUSIVE LICENSE AGREEMENT Between LION BIOTECHNOLOGIES, INC. And POLYBIOCEPT AB Effective as Of: September 14, 2016 EXCLUSIVE AND CO- EXCLUSIVE LICENSE AGREEMENT (November 4th, 2016)

This Exclusive and Co-Exclusive License Agreement (this "Agreement") is made and entered into to be effective as of this 14th day of September, 2016 (the "Effective Date"), by and between

Wave Life Sciences Ltd. – CONFIDENTIAL CO-EXCLUSIVE LICENSE AGREEMENT Between Max-Planck-Innovation GmbH a German Corporation Having a Principal Place of Business at Amalienstr. 33, 80799 Muenchen, Germany - Hereinafter MI - And Wave Life Sciences PTE, Ltd. A Singapore Corporation Having a Principal Place of Business at - Hereinafter WAVE - - MI and WAVE Hereinafter Also Individually Called a Party, or Collectively Called the Parties - (October 9th, 2015)

The Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V. (hereinafter MPG) is a German non-profit scientific research organisation. At the Max-Planck-Institute for Biophysical Chemistry in Goettingen (MPI-BC), a research institute of MPG, Dr. Thomas Tuschl and other scientists of MPI-BC have discovered the sequence and structural features of single-stranded RNA molecules required to mediate target-specific nucleic acid modifications by RNA interference ([***]). The aforementioned invention was funded by the German government. MPG has filed certain Patent Rights (as later defined herein) relating thereto.

Wave Life Sciences Ltd. – CONFIDENTIAL CO-EXCLUSIVE LICENSE AGREEMENT Between Max-Planck-Innovation GmbH a German Corporation Having a Principal Place of Business at Amalienstr. 33, 80799 Muenchen, Germany - Hereinafter MI - And Wave Life Sciences PTE, Ltd. A Singapore Corporation Having a Principal Place of Business at - Hereinafter WAVE - - MI and WAVE Hereinafter Also Individually Called a Party, or Collectively Called the Parties - (September 17th, 2015)

The Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V. (hereinafter MPG) is a German non-profit scientific research organisation. At the Max-Planck-Institute for Biophysical Chemistry in Goettingen (MPI-BC), a research institute of MPG, Dr. Thomas Tuschl and other scientists of MPI-BC have discovered the sequence and structural features of single-stranded RNA molecules required to mediate target-specific nucleic acid modifications by RNA interference ([***]). The aforementioned invention was funded by the German government. MPG has filed certain Patent Rights (as later defined herein) relating thereto.

Co-Exclusive License Agreement (August 17th, 2012)

This Agreement by and among THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (Stanford), an institution of higher education having powers under the laws of the State of California, ALNYLAM PHARMACEUTICALS, INC., a corporation having a principal place of business at 300 Third Street, Cambridge MA 02142, and its Affiliates (Alnylam), and ISIS PHARMACEUTICALS, INC., a corporation having a principal place of business at 1896 Rutherford Road, Carlsbad, CA 92008, and its Affiliates (Isis) (individually, Alnylam and Isis and their respective Affiliates are each a Licensee and collectively, the Licensees) is effective on the 31st day of August, 2005 (Effective Date).

Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Asterisk Denote Omissions. EXCLUSIVE LICENSE AGREEMENT Between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and HERMES BIOSCIENCES, INC. For [**] (UC Case No. [**]) [**] (UC Case No. [**]) [**] (UC Case No. [**]) and CO-EXCLUSIVE LICENSE AGREEMENT Between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and HERMES BIOSCIENCES, INC. For [**] (UC Case No. [**]) [**] (UC Case No. [**]) (October 26th, 2011)

This license agreement (Agreement) is made effective this 1st day of November, 2000 (Effective Date), between The Regents of the University of California, a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 (The Regents), and Hermes Biosciences, Inc., a California corporation, having a principal place of business at 61 Airport Boulevard, Suite B, South San Francisco, California 94080 (Licensee).

Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Asterisk Denote Omissions. EXCLUSIVE LICENSE AGREEMENT Between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and HERMES BIOSCIENCES, INC. For [**] (UC Case No. [**]) [**] (UC Case No. [**]) [**] (UC Case No. [**]) and CO-EXCLUSIVE LICENSE AGREEMENT Between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and HERMES BIOSCIENCES, INC. For [**] (UC Case No. [**]) [**] (UC Case No. [**]) (July 8th, 2011)

This license agreement (Agreement) is made effective this 1st day of November, 2000 (Effective Date), between The Regents of the University of California, a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 (The Regents), and Hermes Biosciences, Inc., a California corporation, having a principal place of business at 61 Airport Boulevard, Suite B, South San Francisco, California 94080 (Licensee).

Amendment to Co-Exclusive License Agreement (May 5th, 2011)

This Amendment to the Alnylam Co-Exclusive License Agreement is made as of March 14, 2011 (Effective Date), by and between Alnylam Pharmaceuticals, Inc. (Alnylam), on the one hand, and Whitehead Institute for Biomedical Research (Whitehead), Massachusetts Institute of Technology (MIT), and Max-Planck-Innovation GmbH (MI).

Fluidigm Corp. – 4060.LICI.006 Harvard CO-EXCLUSIVE LICENSE AGREEMENT Between President and Fellows of Harvard College and Mycometrix Corporation Effective as of October 15, 2000 Re: Harvard Case [***] (January 28th, 2011)

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Fluidigm Corp. – 4060.LICI.006 Harvard CO-EXCLUSIVE LICENSE AGREEMENT Between President and Fellows of Harvard College and Mycometrix Corporation Effective as of October 15, 2000 Re: Harvard Case [***] (December 3rd, 2010)

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Fluidigm Corp. – 4060.LICI.008 Harvard CO-EXCLUSIVE LICENSE AGREEMENT Between President and Fellows of Harvard College and Mycometrix Corporation Effective as of October 15, 2000 Re: Harvard Case #[***] (December 3rd, 2010)

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Fluidigm Corp. – First Amendment to Co-Exclusive License Agreement Between PRESIDENT AND FELLOWS OF HARVARD COLLEGE and MYCOMETRIX CORPORATION (Now Fluidigm Corporation) Re: Harvard Case #[***] (December 3rd, 2010)

This is the first amendment to a co-exclusive license agreement effective October 15, 2000, by and between the President and Fellows of Harvard College, with offices at 1350 Massachusetts Avenue, Suite 727, Cambridge, MA 02138 (Harvard) and Mycometrix Corporation, a California Corporation, with offices at 213 East Grand Avenue, South San Francisco, CA 94080 (Licensee).

Fluidigm Corp. – 4060.LICI.010 Harvard CO-EXCLUSIVE LICENSE AGREEMENT Between President and Fellows of Harvard College and Mycometrix Corporation Effective as of October 15, 2000 Re: Harvard Case #[***] (December 3rd, 2010)

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Fluidigm Corp. – Contract (August 13th, 2008)

[***] Indicates text has been omitted from this Exhibit pursuant to a confidential treatment request and has been filed separately with the Securities and Exchange Commission.

Axis Technologies Group Inc – Co-Exclusive License Agreement for Simplified Daylight Harvesting Technology (July 24th, 2008)
Fluidigm Corp. – Contract (April 14th, 2008)

[***] Indicates text has been omitted from this Exhibit pursuant to a confidential treatment request and has been filed separately with the Securities and Exchange Commission.

Fluidigm Corp. – Contract (April 14th, 2008)

[***] Indicates text has been omitted from this Exhibit pursuant to a confidential treatment request and has been filed separately with the Securities and Exchange Commission.

Fluidigm Corp. – Contract (April 14th, 2008)

[***] Indicates text has been omitted from this Exhibit pursuant to a confidential treatment request and has been filed separately with the Securities and Exchange Commission.

Fluidigm Corp. – First Amendment to Co-Exclusive License Agreement Between PRESIDENT AND FELLOWS OF HARVARD COLLEGE and MYCOMETRIX CORPORATION (Now Fluidigm Corporation) Re: Harvard Case #[***] (April 14th, 2008)

This is the first amendment to a co-exclusive license agreement effective October 15, 2000, by and between the President and Fellows of Harvard College, with offices at 1350 Massachusetts Avenue, Suite 727, Cambridge, MA 02138 (Harvard) and Mycometrix Corporation, a California Corporation, with offices at 213 East Grand Avenue, South San Francisco, CA 94080 (Licensee).

Co-Exclusive License Agreement (June 6th, 2005)

This LICENSE AGREEMENT (Agreement), dated as of June 2, 2005 (the Effective Date), is by and between Edwards Lifesciences PVT, Inc., a Delaware corporation (Edwards), on the one hand, and 3F Therapeutics, Inc., a Delaware corporation (3F), on the other hand. Each of Edwards and 3F may be referred to herein individually as a Party or collectively as the Parties.